RDIF AND CONSORTIUM OF MIDDLE EASTERN FUNDS TO INVEST IN NEW CANCER TREATMENT CENTERS IN MOSCOW REGION
Press release, 20.04.2017
Moscow, 20 April 2017 – The Russian Direct Investment Fund (RDIF) jointly with Mubadala Development Company and other leading Middle Eastern funds announced the investment in the creation of cancer treatment centers in the Moscow region. The corresponding agreement includes the construction, start-up and maintenance of centers in the cities of Podolsk and Balashikha.
The project is implemented under the public-private partnership between the government of the Moscow region and a number of special purpose vehicles. The creditor of the project is Gazprombank.
The area of the center in Podolsk will be 5,000 square meters - the center will provide high-tech assistance to more than 200 patients daily. The center in Balashikha will occupy 7,000 square meters and will serve more than 300 patients daily. Both centers are expected to be launched by the end of 2017.
Kirill Dmitriev, CEO of Russian Direct Investment Fund (RDIF), noted:
“We are pleased to announce the new healthcare project implemented by RDIF. Such investment opportunities are of great interest for our foreign partners. Russia has a great potential for implementation of PPP projects in the healthcare sector. The active use of this mechanism at the regional level will significantly improve the quality of medical services and their accessibility to the population and satisfy the growing demand for high-quality and high-tech medical services.”
Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow. Further information can be found at www.rdif.ru
For additional information contact:
Russian Direct Investment Fund
Director of External Communications
Tel: +7 495 644 34 14, ext. 2141
Mobile: +7 964 726 17 73
Andrew Hayes / Yulianna Vilkos
Tel: +44 (0) 20 7796 4133